Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01638
|
|||||
| Drug Name |
N-desethyl sunitinib
|
|||||
| Synonyms |
N-Desethyl Sunitinib; N-DesethylSunitinib; UNII-42LJ35612R; 42LJ35612R; C20H23FN4O2; N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; SCHEMBL2115189; CHEMBL3542344; DTXSID10437828
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H23FN4O2
|
|||||
| Canonical SMILES |
CCNCCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
|
|||||
| InChI |
InChI=1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-
|
|||||
| InChIKey |
LIZNIAKSBJKPQC-GDNBJRDFSA-N
|
|||||
| CAS Number |
CAS 356068-97-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 370.4 | Topological Polar Surface Area | 86 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | MedchemExpress: N-Desethyl-Sunitinib | |||||
| 2 | P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.